Norihisa Tamura

Norihisa Tamura

Auto-generated profile, based on publicly available information

Norihisa Tamura

Clinical Veterinary Medicine Division Equine Research Institute Japan Racing Association Shimotsuke Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2016 in Development, Growth & Differentiation
Verified
Journal Article
Open access
PDF file
MIMasamichi Ishizuka
Masamichi Ishizuka
EOEri Ohtsuka
Eri Ohtsuka
AIAtsuto Inoue
Atsuto Inoue
MOMirei Odaka
Mirei Odaka
HOHirotaka Ohshima
Hirotaka Ohshima
HHHiromi Hagiwara
Hiromi Hagiwara
Zfp318, a mouse gene with a Cys2/His2 zinc finger motif, is mainly expressed in germ cells in the testis. It encodes two alternative transcripts, which regulate androgen receptor‐mediated transcriptional activation or repression by overexpression of them. However, the role of Zfp318 is still obscure in vivo, especially in spermatogenesis. To elucidate the role of Zfp318 during gamete production, we established a knockout mouse line. Zfp318‐null male mice exhibited infertility, whereas Zfp318‐null female mice displayed normal fertility. ZFP318 was expressed during multiple stages of spermatogenesis, from spermatocytes to round spermatids. The nuclei of secondary spermatocytes showed high levels of expression. Histological analysis and quantitative analysis of DNA content showed decreased numbers of both spermatids in the seminiferous tubules and mature spermatozoa in the epididymides of Zfp318‐null mice. These results suggest that Zfp318 is expressed as a functional protein in testicular germ cells and plays an important role in meiosis during spermatogenesis.

1 July 2020 in Veterinary Record
Verified
Journal Article
Closed access
PDF file
MNMotoi Nomura
Motoi Nomura
TKTaisuke Kuroda
Taisuke Kuroda
NTNorihisa Tamura
Norihisa Tamura
MMMasanori Muranaka
Masanori Muranaka
HNHidekazu Niwa
Hidekazu Niwa
Background: Although Clostridioides difficile ‐associated diseases (CDAD) is considered to be associated with colitis in horses, few studies have been performed with a focus on the characteristics of CDAD in thoroughbred racehorses. Methods: Between 2010 and 2018, a test for C. difficile was performed using faecal samples from 137 thoroughbred racehorses with colitis presenting with diarrhoea and fever. The mortality rate, clinical findings, predisposing factors and the selected treatments were investigated in a retrospective manner. Results: Twenty‐four cases were diagnosed as CDAD and 113 as non‐CDAD. The mortality rate was significantly higher in the CDAD group (83 per cent) than that in the non‐CDAD group (34 per cent). The levels of serum amyloid A, blood urea nitrogen and packed cell volume at initial presentation were also significantly higher, and those of total protein and albumin were significantly lower in the CDAD group. The development of CDAD was associated with the administration of antimicrobials, surgery and hospitalisation. No significant improvement in mortality was observed for any of the selected treatment in both groups. Conclusion: CDAD in thoroughbred racehorses was identified as a high mortality disease with rapid progression of systemic inflammation and deterioration of the circulatory state. Further investigation is required to improve the treatment.

4 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
Teruaki TozakiTeruaki Tozaki
Teruaki Tozaki
AOAoi Ohnuma
Aoi Ohnuma
KNKotono Nakamura
Kotono Nakamura
KHKazuki Hano
Kazuki Hano
MTMasaki Takasu
Masaki Takasu
SNShun-Ichi Nagata
Shun-Ichi Nagata
The creation of genetically modified horses is prohibited in horse racing as it falls under the banner of gene doping. In this study, we developed a test to detect gene editing based on amplicon sequencing using next-generation sequencing (NGS). We designed 1012 amplicons to target 52 genes (481 exons) and 147 single-nucleotide variants (SNVs). NGS analyses showed that 97.7% of the targeted exons were sequenced to sufficient coverage (depth > 50) for calling variants. The targets of artificial editing were defined as homozygous alternative (HomoALT) and compound heterozygous alternative (ALT1/ALT2) insertion/deletion (INDEL) mutations in this study. Four models of gene editing (three homoALT with 1-bp insertions, one REF/ALT with 77-bp deletion) were constructed by editing the myostatin gene in horse fibroblasts using CRISPR/Cas9. The edited cells and 101 samples from thoroughbred horses were screened using the developed test, which was capable of identifying the three homoALT cells containing 1-bp insertions. Furthermore, 147 SNVs were investigated for their utility in confirming biological parentage. Of these, 120 SNVs were amenable to consistent and accurate genotyping. Surrogate (nonbiological) dams were excluded by 9.8 SNVs on average, indicating that the 120 SNV could be used to detect foals that have been produced by somatic cloning or embryo transfer, two practices that are prohibited in thoroughbred racing and breeding. These results indicate that gene-editing tests that include variant calling and SNV genotyping are useful to identify genetically modified racehorses.

20 December 2020 in Equine Veterinary Journal
Verified
Journal Article
Open access
PDF file
TKTaisuke Kuroda
Taisuke Kuroda
YMYohei Minamijima
Yohei Minamijima
HNHidekazu Niwa
Hidekazu Niwa
NTNorihisa Tamura
Norihisa Tamura
HMHiroshi Mita
Hiroshi Mita
YKYoshinori Kasashima
Yoshinori Kasashima
Background: First‐generation cephalosporins have good activity against gram‐positive bacteria and are extensively used in horses. There are few reports of pharmacokinetics and pharmacodynamics (PK/PD) analysis of cephalosporins in horses. Objective: To optimise the dosages of the two first‐generation cephalosporins cephalothin (CET) and cefazolin (CEZ) in horses using PK/PD concepts. Study design: Experimental study with single administration. Methods: Drug plasma concentrations following a single intravenous (i.v.) administration of 22 mg/kg bodyweight (bwt) CET in 12 horses and of 10 mg/kg bwt CEZ in six horses were measured using LC‐MS/MS. Data were modelled using a nonlinear mixed effect modelling followed by Monte Carlo simulations. Minimum inhibitory concentrations (MICs) against Streptococcus zooepidemicus and Staphylococcus aureus isolated from horses were determined by the microbroth dilution method. Results: The percentages of CET and CEZ binding to serum proteins were 19.9% ± 8.4% and 15.2% ± 8.5% respectively. For both CET and CEZ, the MIC 90 against S. zooepidemicus was 0.12 mg/L and against S. aureus was 0.5 mg/L. For CET, to achieve a probability of target attainment (PTA) of 90% for a PK/PD target of a free serum plasma concentration exceeding the MIC 90 for 40% of the dosing interval, an empirical CET dosage regimen of 22 mg/kg bwt q8h and 22 mg/kg bwt q4h i.v. administration were required for S. zooepidemicus and S. aureus respectively. For CEZ, the corresponding dosage regimens were 10 mg/kg bwt q12h and 10 mg/kg bwt q8h. Main limitations: Small sample size only in healthy horses. Conclusions: For CET, more frequent administration than that currently recommended (22 mg/kg bwt q6–12h) is required to empirically control S. aureus infection in horses. For CEZ, less frequent administration compared to the dosage regimen currently proposed (10–22 mg/kg bwt q6h) could control S. zooepidemicus and S. aureus infections in horses.

25 November 2021 in Equine Veterinary Journal
Verified
Journal Article
Open access
PDF file
TKTaisuke Kuroda
Taisuke Kuroda
YMYohei Minamijima
Yohei Minamijima
MNMotoi Nomura
Motoi Nomura
SYShozo Yamashita
Shozo Yamashita
MYMasayuki Yamada
Masayuki Yamada
FSFumio Sato
Fumio Sato
Summary: Background: For medication control in several jurisdictions, withdrawal time is the period of refrain from racing after drug administration. It is set by adding a safety period to an experimental detection time. However, there are no reports of statistical analyses of detection time for the determination of withdrawal time in flunixin meglumine‐treated horses. Objective: To analyse the population pharmacokinetics of flunixin in horses through the generation of a dataset for detection time statistical analysis and predictions via Monte Carlo simulation. Study design: Experimental study. Methods: Drug plasma and urine concentrations following single intravenous administration of flunixin 1.1 mg/kg bodyweight (BW) in 10 horses and multiple administration of q 24 hours for 5 days in 10 horses were measured using liquid chromatography with tandem mass spectrometry (LC‐MS/MS). Data were modelled using a nonlinear mixed effect model followed by Monte Carlo simulation. Irrelevant plasma concentration (IPC) and irrelevant urine concentration (IUC) were calculated using the Toutain approach. Detection times were obtained considering the time after the last administration for selected quantiles of 5000 hypothetical horses under the international screening limit (ISL) proposed by the International Federation of Horseracing Authorities (plasma: 1 ng/mL, urine; 100 ng/mL). Results: For a regimen of 1.1 mg/kg BW q 24 hours, the IPC and IUC values were 2.0 and 73.0 ng/mL respectively. Detection times in plasma above the ISL for 90% of simulated horses were estimated as 74 hours after a single 1.1 mg/kg dose administration, 149 and 199 hours after multiple doses over 5 days at either 24‐ or 12‐hour intervals respectively. Corresponding detection times in urine were 46, 68 and 104 hours respectively. Main limitation: Only female horses were investigated. Conclusions: Statistical detection times for different flunixin meglumine regimens indicated a delay of detection time in plasma after multiple administrations under ISL.

3 February 2022 in Journal of Equine Veterinary Science
Verified
Journal Article
Closed access
KFKentaro Fukuda
Kentaro Fukuda
TKTaisuke Kuroda
Taisuke Kuroda
NTNorihisa Tamura
Norihisa Tamura
HMHiroshi Mita
Hiroshi Mita
HMHirofumi Miyata
Hirofumi Miyata
YKYoshinori Kasashima
Yoshinori Kasashima